AbbVie Presents Data at the 64th American Society of Hematology Annual Meeting Evaluating Epcoritamab Across B-Cell Lymphomas Pharmaceutical Investing
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite's Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis Pharmaceutical Investing
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations Market News
AbbVie Presents Data at the 64th American Society of Hematology Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients Pharmaceutical Investing
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial Life Science Investing
AbbVie Presents Data at the 64th American Society of Hematology Annual Meeting Adds to Robust IMBRUVICA® Science Pharmaceutical Investing
Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth Pharmaceutical Investing
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma Pharmaceutical Investing
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma Pharmaceutical Investing
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
